. 2017 Dec 19;41(6):423–429. doi: 10.4093/dmj.2017.41.6.423

Table 1. Glucagon-like peptide 1 receptor agonists for patients with type 2 diabetes mellitus.

	Mechanism and common use	Weight gain	Hypoglycemia^a	HbA1c reduction, %^a	Side effects	Caution
GLP-1 receptor agonist (exenatide, liraglutide, albiglutide, lixisenatide, dulaglutide)	↑ Glucose-dependent insulin secretion, ↓ postprandial glucagon secretion, ↓ postprandial hyperglycemia, delay gastric emptying, ↑ satiety	No	No	0.6–1.9	GI side effects (nausea, vomiting, diarrhea)	Acute pancreatitis, C-cell hyperplasia, MEN2/MTC family or past history, severe renal or severe bowel disease
	Once or twice daily or once weekly SC injection	No	No	0.6–1.9	GI side effects (nausea, vomiting, diarrhea)

Adapted from Ko et al. [11].

HbA1c, glycosylated hemoglobin; GLP-1, glucagon-like peptide 1; SC, subcutaneous; GI, gastrointestinal; MEN2, multiple endocrine neoplasia 2; MTC, medullary thyroid cancer.

^aMonotherapy.